Market Access
Biotech funding has returned. The bar has moved with it.
For biotech sponsors, the question worth asking is not whether the rebound is real, but what it is actually rewarding.
Oncology
Building a Phase I oncology centre
The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.
Patients
The strategic opportunity: Owning the behaviour layer
Behaviour is the layer that lifestyle, physical performance, and nutrition – together – occupy.
Sales & Marketing
Media Partner
Why BIO-Europe 2026 matters: The evolution of strategic biop...
2026 marks a significant evolution for BIO-Europe.
Digital
AI is redefining decision-making in biopharma R&D
AI has kickstarted a new wave of innovation in biopharma R&D.
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks
